Clinical Observation Of Asthma Tablet Combined With Symbicort Turbuhaler In The Treatment Of Acute Exacerbation Of Cold Stoms Asthma And Effects On T Lymphocyte

Objective:To study and analyze the effect of asthma tablet combined with Symbicort Turbuhaler on bronchial asthma and its effect on T lymphocytes.Methods:120 patients with bronchial asthma were randomly divided into experimental group(60 cases,asthma tablets combined with Symbicort Turbuhaler)and control group(60 cases,Symbicort Turbuhaler).The lung function,clinical efficacy,the ACT scores,humoral immunity index and T lymphocyte subsets were compared between the two groups before and after treatment.Results:1.After treatment,the FEV1,FVC,PEF and other pulmonary function indicators in the treatment group were(3.21±0.51)L,FVC was(2.62 ±0.32)L and PEF was(6.25 ±0.92)L/S,which were better than those in the control group(2.94±0.47)L,(2.21±0.28)L,(5.84±0.93)L/S.The difference between the two groups was statistically significant.(P<0.05).2.The ACT scores of the two groups before treatment were not significantly different(P > 0.05).After treatment,the ACT scores of the two groups were significantly higher than those before treatment(P < 0.05).The total ACT scores of the patients in the treatment group were(23.10±1.52)higher than those in the control group(21.03±1.15).The ACT scores of the patients in the treatment group were significantly higher than those in the control group(P < 0.05).The difference was statistically significant(P < 0.05).3.Before treatment,there was no significant difference in IgA,IgG and IgM between the two groups(P > 0.05),but the IgA,IgG and IgM in the treatment group were(1.42±0.41)g/L,(8.62±1.04)g/L and(0.63±0.15)g/L after treatment,which were higher than those in the control group(1.03±0.33)g/L,(7.92±0.78)g/L and(0.52±0.13)g/L.The difference between the two groups was significant.There was statistical significance(P < 0.05).4.There was no significant difference in T lymphocyte subsets between the two groups before treatment(P > 0.05).After treatment,the T lymphocyte subsets in the treatment group were significantly higher than those in the control group(49.54±5.72)%,(30.79±4.36)%,(23.07±1.82)%,(36.79±3.84)%,CD8+(25.70±1.35)%,CD4+/CD8 +(1.43±0.14)%.The difference between the two groups was significant(P< 0.05).5.After treatment,48.33% of the patients in the treatment group were completely controlled,33.33% of the patients in the treatment group were significantly more effective than those in the control group;the distribution of the curative effect in the treatment group was better than that in the control group;and the total effective rate in the treatment group was 93.33% higher than that in the control group,75.00%.There was a significant difference between the two groups(P<0.05).Conclusion:Asthma tablets combined with Symbicort Turbuhaler in the treatment of bronchial asthma patients have significant effect,can effectively control inflammatory mediators,improve lung function,promote the early recovery of the body,worthy of clinical application.